These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2949920)

  • 1. Human, porcine and bovine ultralente insulin: subcutaneous administration in normal man.
    Owens DR; Vora JP; Heding LG; Luzio S; Ryder RE; Atiea J; Hayes TM
    Diabet Med; 1986; 3(4):326-9. PubMed ID: 2949920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The subcutaneous absorption of human and bovine ultralente insulin formulations.
    Hildebrandt P; Berger A; Vølund A; Kühl C
    Diabet Med; 1985 Sep; 2(5):355-9. PubMed ID: 2951089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of beef ultralente for basal insulin delivery: plasma insulin concentrations after chronic ultralente administration in patients with IDDM.
    Rizza RA; O'Brien PC; Service FJ
    Diabetes Care; 1986; 9(2):120-3. PubMed ID: 3698778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of human ultralente- and lente-based twice-daily injection regimens.
    Tunbridge FK; Newens A; Home PD; Davis SN; Murphy M; Burrin JM; Alberti KG; Jensen I
    Diabet Med; 1989 Aug; 6(6):496-501. PubMed ID: 2527130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles.
    Lindström T; Olsson PO; Arnqvist HJ
    Scand J Clin Lab Invest; 2000 Aug; 60(5):341-7. PubMed ID: 11003253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the safety and effectiveness of human and bovine long-acting insulins.
    Selam JL; Turner D; Woertz L; Eichner HL; Lauritano A; Charles MA
    Diabetes Res; 1989 Nov; 12(3):131-4. PubMed ID: 2635094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Miscibility of human and bovine ultralente insulin with soluble insulin.
    Mühlhauser I; Broermann C; Tsotsalas M; Berger M
    Br Med J (Clin Res Ed); 1984 Dec; 289(6459):1656-7. PubMed ID: 6439364
    [No Abstract]   [Full Text] [Related]  

  • 9. Human ultralente insulin: a comparison with porcine lente insulin as a twice-daily insulin in insulin-dependent diabetic patients with fasting hyperglycaemia.
    Francis AJ; Hanning I; Alberti KG
    Diabetes Res; 1986 Jun; 3(5):263-8. PubMed ID: 3527523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two ultralente insulin preparations with protamine zinc insulin in clinically normal cats.
    Broussard JD; Peterson ME
    Am J Vet Res; 1994 Jan; 55(1):127-31. PubMed ID: 8141485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human ultralente insulin.
    Holman RR; Steemson J; Darling P; Reeves WG; Turner RC
    Br Med J (Clin Res Ed); 1984 Mar; 288(6418):665-8. PubMed ID: 6421424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin.
    Riccio A; Avogaro A; Valerio A; Zappella A; Tiengo A; Del Prato S
    Diabetes Care; 1994 Jun; 17(6):535-40. PubMed ID: 8082521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique.
    Scholtz HE; Pretorius SG; Wessels DH; Becker RH
    Diabetologia; 2005 Oct; 48(10):1988-95. PubMed ID: 16160867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of subcutaneously administered human, porcine and bovine neutral soluble insulin to normal man.
    Owens DR; Jones MK; Birtwell AJ; Burge CT; Jones IR; Heyburn PJ; Hayes TM; Heding LG
    Horm Metab Res; 1984 Dec; 16 Suppl 1():195-9. PubMed ID: 6152435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early morning glycaemia and the metabolic consequences of delaying breakfast/morning insulin. A comparison of continuous subcutaneous insulin infusion and multiple injection therapy with human isophane or human ultralente insulin at bedtime in insulin-dependent diabetics.
    Haakens K; Hanssen KF; Dahl-Jørgensen K; Vaaler S; Torjesen P; Try K
    Scand J Clin Lab Invest; 1989 Nov; 49(7):653-9. PubMed ID: 2692136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of human insulin zinc suspension (recombinant DNA) in normal man: a comparison with porcine insulin zinc suspension.
    Frier BM; Sullivan FM; Mair FS; Koch IM; Scotton JB
    Diabet Med; 1984 Sep; 1(3):219-21. PubMed ID: 6242801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and morphological characterization of ultralente insulin crystals by atomic force microscopy: evidence of hydrophobically driven assembly.
    Yip CM; DeFelippis MR; Frank BH; Brader ML; Ward MD
    Biophys J; 1998 Sep; 75(3):1172-9. PubMed ID: 9726919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of premixed with patient-mixed insulins.
    Corcoran JS; Yudkin JS
    Diabet Med; 1986 May; 3(3):246-9. PubMed ID: 2951178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy.
    Martin GJ; Rand JS
    J Feline Med Surg; 2001 Mar; 3(1):23-30. PubMed ID: 11716627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term use of intramuscular insulin therapy in a type I diabetic patient with subcutaneous insulin resistance.
    Brossard JH; Havrankova J; Rioux D; Bertrand S; D'Amour P
    Diabet Med; 1993 Mar; 10(2):174-6. PubMed ID: 8458196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.